Bevacizumab Beyond Disease Progression Plus Carboplatin-Based Doublet in Platinum-Sensitive Ovarian Cancer
February 23, 2021 6:00 pmBy Matthew Stenger
In the phase III MITO16b/MANGO–OV2/ENGOT–ov17 trial, investigators found that treatment with a carboplatin-based doublet plus bevacizumab beyond disease progression significantly improved progression-free survival vs a carboplatin-based doublet alone in women with platinum-sensitive ovarian cancer who experienced disease … Read more